Should I Buy PCRX Stock in 2026?
Data-driven analysis and honest assessment for Pacira Biosciences Inc
Current Price: $23.86P/E: 149.1
Decision Score
Weak
Based on 6 fundamental factors
Score Breakdown:
Very high P/E of 149.1 suggests overvaluation
Declining -0%
Thin margins (0% net)
Financial health data limited
Excellent FCF yield of 8.5%
No recent insider activity
Key Investment Metrics
Current Price
$23.86
P/E Ratio
149.13
Revenue Growth
0.1%
Profit Margin
0.0%
Market Cap
$1.0B
Dividend Yield
None
How PCRX Compares to Competitors
Understanding how PCRX stacks up against peers helps inform your investment decision.
How PCRX Compares to Peers
Upcoming Events for PCRX
+5 Reasons TO Buy PCRX
1. High free cash flow yield of 8.5%
strongFCF yield above 5% means substantial cash generation for dividends, buybacks, or reinvestment.
2. High gross margins of 63%
moderateGross margins above 50% typically indicate strong brand value or intellectual property moats.
-5 Reasons NOT to Buy PCRX
1. Expensive valuation at 149x earnings
high riskP/E of 149 is significantly above averages. High expectations leave little room for disappointment.
2. Thin profit margins of 0.0%
high riskLow margins provide little cushion against cost increases or pricing pressure.
3. High PEG ratio of 11.2
high riskPEG above 2 suggests expensive relative to growth rate.
4. Small-cap volatility risk
medium riskMarket cap under $2B means higher volatility and lower liquidity.
5. Minimal revenue growth
low riskGrowth of 0.1% barely keeps pace with inflation.
Who Should Buy PCRX?
Investment Profile
Risk Level
Very High
Recommended Holding Period
3-5 years
Best For:
- ✓
Momentum Traders
High-growth profile attracts momentum
Not Suitable For:
- ✗
Growth Investors
Limited 0% growth may disappoint
- ✗
Value Investors
Premium P/E of 149 doesn't fit value criteria
- ✗
Income-Focused Retirees
No dividend paid
- ✗
Risk-Averse Investors
Very High risk may cause uncomfortable volatility
Consider These Alternatives
If you're interested in PCRX, compare these Health Care peers:
Pro tip: Compare PCRX directly with competitors using our comparison tool to see which stock better fits your criteria.
Get the Full Picture
Access AI-powered insights, DCF valuations, insider trading data, and real-time analysis for PCRX
Frequently Asked Questions
What is PCRX stock price today?
PCRX (Pacira Biosciences Inc) stock is trading at $23.86 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).
Is PCRX stock going up or down today?
PCRX stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.
Should I buy PCRX stock now?
The decision to buy PCRX depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.
Is PCRX a buy, hold, or sell right now?
Our AI-powered analysis provides buy/hold/sell recommendations for PCRX based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.
Is PCRX stock overvalued or undervalued?
PCRX currently trades at a P/E ratio of 149.13, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if PCRX is fairly priced.
What is PCRX's P/E ratio?
PCRX has a price-to-earnings (P/E) ratio of 149.13, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.
What is PCRX's market cap?
PCRX (Pacira Biosciences Inc) has a market capitalization of $1.03 billion, making it a small-cap stock.
What is PCRX's price to book ratio?
PCRX trades at a price-to-book (P/B) ratio of 1.37, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.
Deep Dive Analysis
Explore comprehensive analysis tools to make an informed decision about Pacira Biosciences Inc
Full Stock Analysis
Complete PCRX overview with charts and data
Is PCRX Undervalued?
DCF valuation and intrinsic value analysis
Dividend Analysis
Yield, payout ratio, and dividend history
Growth Analysis
Revenue, earnings, and expansion metrics
Financial Health
Debt, liquidity, and balance sheet strength
Price Prediction
2026 forecast and price targets
Stock Forecast
12-month price forecast and analyst targets
Earnings Date
Next earnings date and historical results
Compare Before You Buy
See how PCRX stacks up against its competitors
Similar Investment Decisions
Explore investment analyses for stocks similar to Pacira Biosciences Inc
Complete PCRX Analysis
Compare PCRX With
Disclaimer
This analysis is for informational purposes only and should not be considered financial advice. The decision score and recommendations are based on quantitative factors and do not account for all risks, your personal financial situation, or qualitative factors. Always do your own research and consider consulting with a financial advisor before making investment decisions.